The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030. The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.
The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.
The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.
Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.
The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.
The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.
Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.
Tuberculosis Therapeutics Market Report Highlights
- Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition
- Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs
- Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.
- The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.
- MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.
Table of Contents
Chapter 1 Tuberculosis Therapeutics Market: Methodology And Scope1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.11 List of Abbreviations
Chapter 2 Tuberculosis Therapeutics Market: Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Tuberculosis Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rise in the prevalence of tuberculosis
3.3.1.2 Increasing investment for healthcare infrastructure
3.3.1.3 Growing number of geriatric population
3.3.2 Market Restraint Analysis
3.3.2.1 High cost of multidrug-resistant TB
3.3.2.2 Side effects linked with anti-tuberculosis drugs
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Tuberculosis Therapeutics Market: Competitive Landscape
4.1 Recent Developments & Impact Analysis, By Key Market Participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Tuberculosis Therapeutics Market: Disease Type Business Analysis
5.1 Definition And Scope
5.2 Disease Type Market Share Analysis, 2022 & 2030
5.3 Global Tuberculosis Therapeutics Market, By Disease Type, 2018 To 2030
5.4 Tuberculosis Therapeutics Market: Disease Type Movement Analysis
5.5 Active Tb
5.5.1 Active Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6 Latent Tb
5.6.1 Latent Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Tuberculosis Therapeutics Market: Therapy Business Analysis
6.1 Definition and Scope
6.2 Therapy Market Share Analysis, 2022 & 2030
6.3 Global Tuberculosis Therapeutics Market, By Therapy, 2018 To 2030
6.4 Tuberculosis Therapeutics Market: Therapy Movement Analysis
6.5 First-Line Therapy
6.5.1 First-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6 Second-Line Therapy
6.6.1 Second-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Tuberculosis Therapeutics Market: Route of Administration Business Analysis
7.1 Definition and Scope
7.2 Route of Administration Market Share Analysis, 2022 & 2030
7.3 Global Tuberculosis Therapeutics Market, By Route of Administration, 2018 To 2030
7.4 Tuberculosis Therapeutics Market: Route of Administration Movement Analysis
7.5 Oral
7.5.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 Parentral
7.6.1 Parentral Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.7 Others
7.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Tuberculosis Therapeutics Market: Dosage Form Business Analysis
8.1 Definition and Scope
8.2 Dosage Form Market Share Analysis, 2022 & 2030
8.3 Global Tuberculosis Therapeutics Market, By Dosage Form, 2018 To 2030
8.4 Tuberculosis Therapeutics Market: Dosage Form Movement Analysis
8.5 Tablets
8.5.1 Tablets Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6 Capsules
8.6.1 Capsules Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.7 Injections
8.7.1 Injections Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.8 Others
8.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 9 Tuberculosis Therapeutics Market: Distribution Channel Business Analysis
9.1 Definition and Scope
9.2 Distribution Channel Market Share Analysis, 2022 & 2030
9.3 Global Tuberculosis Therapeutics Market, By Distribution Channel, 2018 To 2030
9.4 Tuberculosis Therapeutics Market: Distribution Channel Movement Analysis
9.5 Hospital Pharmacy
9.5.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.6 Retail Pharmacy
9.6.1 Reatail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.7 Online Pharmacy
9.7.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.8 Others
9.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 10 Tuberculosis Therapeutics Market: Regional Business Analysis
10.1 Definition & Scope
10.2 Regional Market Share Analysis, 2022 & 2030
10.3 Regional Market Dashboard
10.4 Regional Market Snapshot
10.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
10.5.1 North America
10.5.2 Europe
10.5.3 Asia Pacific
10.5.4 Latin America
10.5.5 Mea
10.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
10.7 North America
10.7.1 North America Tuberculosis Therapeutics Market Estimates And Forecast, 2018 - 2030 (USD Million)
10.7.2 U.S.
10.7.2.1 U.S. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.7.2.2 Key Country Dynamics
10.7.2.3 Regulatory Framework
10.7.2.4 Competitive Scenario
10.7.2.5 Import Export Scenario
10.7.2.6 Investments Scenario
10.7.3 Canada
10.7.3.1 Canada tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.7.3.2 Key Country Dynamics
10.7.3.3 Regulatory Framework
10.7.3.4 Competitive Scenario
10.7.3.5 Import Export Scenario
10.7.3.6 Investments Scenario
10.8 Europe
10.8.1 Europe Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.2 U.K.
10.8.2.1 U.K. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.2.2 Key Country Dynamics
10.8.2.3 Regulatory Framework
10.8.2.4 Competitive Scenario
10.8.2.5 Import Export Scenario
10.8.2.6 Investments Scenario
10.8.3 Germany
10.8.3.1 Germany Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.3.2 Key Country Dynamics
10.8.3.3 Regulatory Framework
10.8.3.4 Competitive Scenario
10.8.3.5 Import Export Scenario
10.8.3.6 Investments Scenario
10.8.4 Spain
10.8.4.1 Spain tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.8.4.2 Key Country Dynamics
10.8.4.3 Regulatory Framework
10.8.4.4 Competitive Scenario
10.8.4.5 Import Export Scenario
10.8.4.6 Investments Scenario
10.8.5 France
10.8.5.1 France tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.8.5.2 Key Country Dynamics
10.8.5.3 Regulatory Framework
10.8.5.4 Competitive Scenario
10.8.5.5 Import Export Scenario
10.8.5.6 Investments Scenario
10.8.6 Italy
10.8.6.1 Italy tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.8.6.2 Key Country Dynamics
10.8.6.3 Regulatory Framework
10.8.6.4 Competitive Scenario
10.8.6.5 Import Export Scenario
10.8.6.6 Investments Scenario
10.8.7 Russia
10.8.7.1 Russia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.8.7.3 Regulatory Framework
10.8.7.4 Competitive Scenario
10.8.7.5 Import Export Scenario
10.8.7.6 Investments Scenario
10.8.8 Denmark
10.8.8.1 Denmark Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.8.2 Key Country Dynamics
10.8.8.3 Regulatory Framework
10.8.8.4 Competitive Scenario
10.8.8.5 Import Export Scenario
10.8.8.6 Investments Scenario
10.8.9 Sweden
10.8.9.1 Sweden Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.9.2 Key Country Dynamics
10.8.9.3 Regulatory Framework
10.8.9.4 Competitive Scenario
10.8.9.5 Import Export Scenario
10.8.9.6 Investments Scenario
10.8.10 Norway
10.8.10.1 Norway Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.8.10.2 Key Country Dynamics
10.8.10.3 Regulatory Framework
10.8.10.4 Competitive Scenario
10.8.10.5 Import Export Scenario
10.8.10.6 Investments Scenario
10.9 Asia Pacific
10.9.1 Asia-Pacific Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.2 Japan
10.9.2.1 Japan Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.2.2 Key Country Dynamics
10.9.2.3 Regulatory Framework
10.9.2.4 Competitive Scenario
10.9.2.5 Import Export Scenario
10.9.2.6 Investments Scenario
10.9.3 China
10.9.3.1 China Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.3.2 Key Country Dynamics
10.9.3.3 Regulatory Framework
10.9.3.4 Competitive Scenario
10.9.3.5 Import Export Scenario
10.9.3.6 Investments Scenario
10.9.4 India
10.9.4.1 India Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.4.2 Key Country Dynamics
10.9.4.3 Regulatory Framework
10.9.4.4 Competitive Scenario
10.9.4.5 Import Export Scenario
10.9.4.6 Investments Scenario
10.9.5 South Korea
10.9.5.1 South Korea Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.5.2 Key Country Dynamics
10.9.5.3 Regulatory Framework
10.9.5.4 Competitive Scenario
10.9.5.5 Import Export Scenario
10.9.5.6 Investments Scenario
10.9.6 Thailand
10.9.6.1 Thailand Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.9.6.2 Key Country Dynamics
10.9.6.3 Regulatory Framework
10.9.6.4 Competitive Scenario
10.9.6.5 Import Export Scenario
10.9.6.6 Investments Scenario
10.9.7 Australia
10.9.7.1 Australia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
10.9.7.2 Key Country Dynamics
10.9.7.3 Regulatory Framework
10.9.7.4 Competitive Scenario
10.9.7.5 Import Export Scenario
10.9.7.6 Investments Scenario
10.10 Latin America
10.10.1 Latin America Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.10.2 Brazil
10.10.2.1 Brazil Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.10.2.2 Key Country Dynamics
10.10.2.3 Regulatory Framework
10.10.2.4 Competitive Scenario
10.10.2.5 Import Export Scenario
10.10.2.6 Investments Scenario
10.10.3 Mexico
10.10.3.1 Mexico Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.10.3.2 Key Country Dynamics
10.10.3.3 Regulatory Framework
10.10.3.4 Competitive Scenario
10.10.3.5 Import Export Scenario
10.10.3.6 Investments Scenario
10.10.4 Argentina
10.10.4.1 Argentina Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.10.4.2 Key Country Dynamics
10.10.4.3 Regulatory Framework
10.10.4.4 Competitive Scenario
10.10.4.5 Import Export Scenario
10.10.4.6 Investments Scenario
10.11 MEA
10.11.1 MEA Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.11.2 South Africa
10.11.2.1 South Africa Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.11.2.2 Key Country Dynamics
10.11.2.3 Regulatory Framework
10.11.2.4 Competitive Scenario
10.11.2.5 Import Export Scenario
10.11.2.6 Investments Scenario
10.11.3 Saudi Arabia
10.11.3.1 Saudi Arabia Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.11.3.2 Key Country Dynamics
10.11.3.3 Regulatory Framework
10.11.3.4 Competitive Scenario
10.11.3.5 Import Export Scenario
10.11.3.6 Investments Scenario
10.11.4 UAE
10.11.4.1 UAE Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.11.4.2 Key Country Dynamics
10.11.4.3 Regulatory Framework
10.11.4.4 Competitive Scenario
10.11.4.5 Import Export Scenario
10.11.4.6 Investments Scenario
10.11.5 Kuwait
10.11.5.1 Kuwait Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
10.11.5.2 Key Country Dynamics
10.11.5.3 Regulatory Framework
10.11.5.4 Competitive Scenario
10.11.5.5 Import Export Scenario
10.11.5.6 Investments Scenario
Chapter 11 Tuberculosis Therapeutics Market: Company Profiling
11.1 Company Profiles
11.1.1 Astrazeneca
11.1.1.1 Company Overview
11.1.1.2 Financial Performance
11.1.1.3 Product Benchmarking
11.1.1.4 Strategic Initiatives
11.1.2 Johnson & Johnson Services, Inc.
11.1.2.1 Company Overview
11.1.2 2.Financial Performance
11.1.2.3 Product Benchmarking
11.1.2.4 Strategic Initiatives
11.1.3 Eli Lilly And Company
11.1.3.1 Company Overview
11.1.3.2 Financial Performance
11.1.3.3 Product Benchmarking
11.1.3.4 Strategic Initiatives
11.1.4 F. Hoffmann-La Roche Ltd.
11.1.4.1 Company Overview
11.1.4.2 Financial Performance
11.1.4.3 Product Benchmarking
11.1.4.4 Strategic Initiatives
11.1.5 Viatris Inc. (Mylan N.V.)
11.1.5.1 Company Overview
11.1.5.2 Financial Performance
11.1.5.3 Product Benchmarking
11.1.5.4 Strategic Initiatives
11.1.6 Teva Pharmaceutical Industries, Ltd.
11.1.6.1 Company Overview
11.1.6.2 Financial Performance
11.1.6.3 Product Benchmarking
11.1.6.4 Strategic Initiatives
11.1.7 Sanofi
11.1.7.1 Company Overview
11.1.7.2 Financial Performance
11.1.7.3 Product Benchmarking
11.1.7.4 Strategic Initiatives
11.1.8 Novartis Ag
11.1.8.1 Company Overview
11.1.8.2 Financial Performance
11.1.8.3 Product Benchmarking
11.1.8.4 Strategic Initiatives
11.1.9 Sun Pharmaceutical Industries Ltd.
11.1.9.1 Company Overview
11.1.9.2 Financial Performance
11.1.9.3 Product Benchmarking
11.1.9.4 Strategic Initiatives
11.1.10 Pfizer Inc.
11.1.10.1 Company Overview
11.1.10.2 Financial Performance
11.1.10.3 Product Benchmarking
11.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Tuberculosis Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Tuberculosis Therapeutics Market, By Drug type, 2018 - 2030 (USD Million)
Table 6 North America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 7 North America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 8 North America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 9 North America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 North America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 11 North America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 U.S. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 13 U.S. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 14 U.S. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 U.S. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 16 U.S. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Canada Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 18 Canada Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 19 Canada Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 20 Canada Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 21 Canada Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 Europe Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 23 Europe Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 24 Europe Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 25 Europe Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Europe Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 27 Europe Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Germany Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 29 Germany Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 30 Germany Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 31 Germany Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 32 Germany Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 33 U.K. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 34 U.K. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 35 U.K. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 U.K. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 37 U.K. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 France Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 39 France Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 40 France Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 41 France Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 42 France Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Italy Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 44 Italy Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 45 Italy Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 46 Italy Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 47 Italy Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Spain Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 49 Spain Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 50 Spain Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 51 Spain Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 52 Spain Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 Denmark Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 54 Denmark Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 55 Denmark Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 56 Denmark Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 57 Denmark Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 58 Sweden Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 59 Sweden Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 60 Sweden Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Sweden Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 62 Sweden Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Norway Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 64 Norway Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 65 Norway Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 66 Norway Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 67 Norway Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 68 Asia Pacific Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 69 Asia Pacific Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 70 Asia Pacific Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 71 Asia Pacific Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 72 Asia Pacific Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 73 Asia Pacific Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 74 Japan Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 75 Japan Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 76 Japan Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 77 Japan Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 78 Japan Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 79 China Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 80 China Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 81 China Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 82 China Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 83 China Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 84 India Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 85 India Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 86 India Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 India Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 88 India Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 89 South Korea Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 90 South Korea Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 91 South Korea Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 92 South Korea Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 93 South Korea Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 94 Australia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 95 Australia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 96 Australia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 97 Australia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 98 Australia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 99 Thailand Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 100 Thailand Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 101 Thailand Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 102 Thailand Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 103 Thailand Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 104 Latin America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 105 Latin America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 106 Latin America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 107 Latin America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 108 Latin America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 109 Latin America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 110 Brazil Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 111 Brazil Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 112 Brazil Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 113 Brazil Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 114 Brazil Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 115 Mexico Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 116 Mexico Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 117 Mexico Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 118 Mexico Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 119 Mexico Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 120 Argentina Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 121 Argentina Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 122 Argentina Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 123 Argentina Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 124 Argentina Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 125 Middle East & Africa Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 126 Middle East & Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 127 Middle East & Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 131 Saudi Arabia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 132 Saudi Arabia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 133 Saudi Arabia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 134 Saudi Arabia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 135 Saudi Arabia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 136 South Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 137 South Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 138 South Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 139 South Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 140 South Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 141 UAE Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 142 UAE Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 143 UAE Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 144 UAE Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 145 UAE Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 146 Kuwait Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
Table 147 Kuwait Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
Table 148 Kuwait Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 149 Kuwait Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
Table 150 Kuwait Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Tuberculosis Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Tuberculosis therapeutics market: Disease type outlook and key takeaways
Fig. 16 Tuberculosis therapeutics market: Disease type movement analysis & market share 2022 & 2030
Fig. 17 Active TB market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Latent TB market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Tuberculosis therapeutics market: Therapy outlook and key takeaways
Fig. 20 Tuberculosis therapeutics market: Therapy movement analysis & market share 2022 & 2030
Fig. 21 First-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Second-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Tuberculosis therapeutics market: Route of administration outlook and key takeaways
Fig. 24 Tuberculosis therapeutics market: Route of administration movement analysis & market share 2022 & 2030
Fig. 25 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Tuberculosis therapeutics market: Dosage form outlook and key takeaways
Fig. 29 Tuberculosis therapeutics market: Dosage form movement analysis & market share 2022 & 2030
Fig. 30 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Injections market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Tuberculosis therapeutics market: Distribution channel outlook and key takeaways
Fig. 35 Tuberculosis therapeutics market: Distribution channel movement analysis & market share 2022 & 2030
Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Regional Marketplace: Key Takeaways
Fig. 41 Regional Outlook, 2022 & 2030
Fig. 42 Regional Market Dashboard
Fig. 43 Regional Market Place: Key Takeaways
Fig. 44 North America, SWOT Analysis
Fig. 45 Europe, SWOT Analysis
Fig. 46 Asia Pacific, SWOT Analysis
Fig. 47 Latin America, SWOT Analysis
Fig. 48 MEA, SWOT Analysis
Fig. 49 North America
Fig. 50 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 51 U.S.
Fig. 52 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 53 Canada
Fig. 54 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 55 Europe
Fig. 56 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 57 U.K.
Fig. 58 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 59 Germany
Fig. 60 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 61 France
Fig. 62 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 63 Italy
Fig. 64 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 65 Spain
Fig. 66 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 67 Denmark
Fig. 68 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 69 Sweden
Fig. 70 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 71 Norway
Fig. 72 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 73 Asia Pacific
Fig. 74 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 75 Japan
Fig. 76 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 77 China
Fig. 78 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 79 India
Fig. 80 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 81 Australia
Fig. 82 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 83 Thailand
Fig. 84 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 85 South Korea
Fig. 86 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 87 Latin America
Fig. 88 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 89 Brazil
Fig. 90 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 91 Mexico
Fig. 92 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 93 Argentina
Fig. 94 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 95 MEA
Fig. 96 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 97 South Africa
Fig. 98 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 99 Saudi Arabia
Fig. 100 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 101 UAE
Fig. 102 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 103 Kuwait
Fig. 104 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 105 Strategy Mapping
Companies Mentioned
- Astrazeneca
- Johnson & Johnson Services, Inc.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Viatris Inc. (Mylan N.V.)
- Teva Pharmaceutical Industries, Ltd.
- Sanofi
- Novartis Ag
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.01 Billion |
| Forecasted Market Value ( USD | $ 2.99 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
